Doctor Evidence collaborated on the underlying systematic review for new guideline published by leading oncology association

SANTA MONICA, CA (PRWEB) Feb 14, 2018-Guideline addresses the management of side effects from immune checkpoint inhibitors treatments

Doctor Evidence (DRE), a global health technology and data company, is proud to have performed the systematic review of evidence, through the GROWTH program, in support of a new guideline issued by the American Society of Clinical Oncology, Inc. (ASCO®), the world's leading professional organization representing physicians who care for people with cancer, in collaboration with the National Comprehensive Cancer Network® (NCCN®). The organizations collaborated to develop comprehensive guidelines to help clinicians with optimal strategies for the identification and diagnosis of adverse events associated with immune checkpoint inhibitors and to offer guidance on their safe management.